Craif | Realization of a society where people achieve longevity
2026.04.24PressCraif Opens Bio-AI Laboratory in San Diego, U.S.
2026.04.24PressCraif Appoints Takeo Mukai as CFO Through Local U.S. Hire ~ Driving Non-Linear Growth of Craif's Global Business with Extensive Experience Leading Exits as CEO/COO/CFO Across Multiple U.S. Healthcare Companies ~
2025.04.28PressCraif Raises US＄22 million in Series C Funding, Accelerates U.S. Expansion and R&D
Using Craif's proprietary technology, we detect cancer-specific signals via AI from microRNAs—molecules that play an important role in the onset and progression of cancer. This technology powers our urine-based cancer risk test, miSignal Scan*, which enables early detection of cancer risk even before symptoms appear. We are also advancing the development of a medical device in both Japan and the United States, offering a new option to support the early detection and accurate diagnosis of pancreatic cancer. *Available only in Japan
Currently available only in Japan.
Through our proprietary biomarker analysis platform NANO IP® (NANO Intelligence Platform®)—which decodes a wide range of biological signals such as DNA and RNA found in body fluids like urine—and by combining it with advanced AI algorithms, Craif is pioneering a Bio-AI approach.
This integrated technology enables us to develop next-generation diagnostic tests and medical devices aimed at the early detection of diseases such as cancer, as well as the realization of personalized treatment tailored to each individual.
